Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
2007
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
Computational Radiomics System to Decode the Radiographic Phenotype
2017 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
1999
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Molecular imaging in drug development
2008 Standout
Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET
2012
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
2009
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
2002
Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methods
2000
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)
2001
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
Thyroid cancer
2016 Standout
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
2002
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Monitoring chemotherapy and radiotherapy of solid tumors
2006
[18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction?
2003
Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives
2004 Standout
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey
2004
FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy
2004
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
2003
Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells
2005
Imaging in the era of molecular oncology
2008 StandoutNature
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
2008
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
2007
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Esophageal Cancer
2003 Standout
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
The role of positron emission tomography (PET) in the management of lymphoma patients
1999
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
2010
Machine Learning methods for Quantitative Radiomic Biomarkers
2015 Standout
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
2002
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD
2005
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
The prevalence of episodic pain in cancer: a survey of hospice patients on admission
2001
The α folate receptor is highly activated in malignant pleural mesothelioma
2001
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica
2013
Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience
2005
Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography
2001
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion Glycolysis
1999
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
2001
Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future
2011
Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer
2009
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
2007 Standout
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
2004
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
2005
Overview of early response assessment in lymphoma with FDG-PET
2007
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
1998
Clinical imaging of cancer metastasis
2000
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
2005 Standout
Advances in Malignant Mesothelioma
2005 Standout
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
2008
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
2005
Emerging DNA topoisomerase inhibitors as anticancer drugs
2004
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
2003
Use of PET for monitoring cancer therapy and for predicting outcome.
2005
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma
2005
Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice.
2005
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017
2017 Standout
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
2001
Positron Emission Tomography As an Imaging Biomarker
2006
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
2006
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
2007
Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma
2002
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies
2001
Positron-Emission Tomography and Assessment of Cancer Therapy
2006
Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography
2005
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors
2005
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
2004
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
2005
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
2002
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.
2005
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
2003
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
2001
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer
2005
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Imaging DNA synthesis in vivo with 18F-FMAU and PET.
2005
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
2005
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma
2001
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
2001
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
2000
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
2010
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
2007
Monitoring cancer treatment with PET/CT: does it make a difference?
2007
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
2007 Standout
Works of R. Thödtmann being referenced
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
2007
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
1998
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours
2003
Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.
1997
Clinical and pharmacoklnetic evaluation of the new blsnaphtalamlde LU 79553 administered every 21 days in patients with solid tumors: An EORTC/ECSG study
1997
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
1998
Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
1999
Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin
1999
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
1999